(S,R)-WT IDH1 Inhibitor 2 (GSK321) 是一个有效的选择性突变型IDH1抑制剂，抑制 R132G、R132C、R132H 和 WT IDH1 的IC50值分别为 2.9、3.8、4.6 和 46 nM，选择性比 IDH2 高出 100 倍。(S,R)-WT IDH1 Inhibitor 2 诱导细胞内 2-HG 减少，髓细胞分化阻滞失效，在白血病母细胞和更不成熟的干细胞水平诱导粒细胞分化。(S,R)-WT IDH1 Inhibitor 2 可用于急性髓系白血病 (AML) 及其他癌症的研究。

(S,R)-WT IDH1 Inhibitor 2 (GSK321) is a potent, selective mutant IDH1 inhibitor with IC 50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-WT IDH1 Inhibitor 2 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-WT IDH1 Inhibitor 2 can be used for research of acute myeloid leukemia (AML) and other cancers [1].

(S,R)-WT IDH1 Inhibitor 2 (GSK321; 0.1-10000 nM; 24 h) inhibits intracellular 2-HG production in HT1080 cells with an EC 50 value of 85 nM [1]. (S,R)-WT IDH1 Inhibitor 2 (0-5 μM; 48 h; HT1080 fibrosarcoma cells) leads to reduction of histone H3K9 dimethylation (H3K9me2) [1]. (S,R)-WT IDH1 Inhibitor 2 (3 μM; 22 d) decreases intracellular 2-HG in a dose-dependent manner (R132G, 0.13-fold; R132C, 0.15-fold; R132H, 0.29-fold) [1]. (S,R)-WT IDH1 Inhibitor 2 (3 μM; 15 d) affects proliferation of primary IDH1 mutant AML cells [1]. (S,R)-WT IDH1 Inhibitor 2 (3 μM; 9 d) induces differentiation in primary IDH1 mutant AML blasts and immature stem-like cells [1]. Cell Viability Assay [1] Cell Line: IDH1 mutant AML cells Concentration: 3 μM Incubation Time: 15 days Result: Increased in cell numbers (2-fold to 15-fold) in IDH1 mutant AML cells. Cell Cycle Analysis [1] Cell Line: IDH1 mutant AML cells Concentration: 3 μM Incubation Time: 15 days Result: Decreased in quiescent (G0)-phase cells and increased in G1-phase in R132G IDH1. Western Blot Analysis [1] Cell Line: HT1080 fibrosarcoma cells Concentration: 0, 0.5 and 5 μM Incubation Time: 48 hours Result: Induced markedly decreased H3K9me2 levels.

(S,R)-WT IDH1 Inhibitor 2 (GSK321; 150 mg/kg; i.p.; daily, for 15 d; male CD-1 mice with IDH1 mutant AML xenograft) reduces leukemic blasts in vivo [1]. Animal Model: Male CD-1 mice with IDH1 mutant AML xenograft [1] Dosage: 150 mg/kg Administration: Intraperitoneal injection; daily, for 15 days Result: Decreased in 2HG in IDH1-mutant AML cells. Decreased in the percentage of blast cells ( SSClow CD45 low/+ ) and a relative increase in mature lymphoid and granulocytic/monocytic cells.

1816272-18-0

C28H28FN5O3

501.55

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years